Pembrolizumab Maintenance Yields Enduring Responses in HER2– Breast Cancer
Further research may validate identified biomarkers and refine patient selection criteria for pembrolizumab therapy in breast cancer.
FDA Approves Tovorafenib for Relapsed/Refractory Low-Grade Glioma
The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.
Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC
Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.
FDA Approves Lutetium Lu 177 Dotatate in Pediatric SSTR+ GEP-NETs
Data from 2 NETTER trials support lutetium Lu 177 dotatate's approval in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Tislelizumab Earns European Approval in Non–Small Cell Lung Cancer
A series of phase 3 findings support the European approval of tislelizumab as a first-line and second-line treatment for non–small cell lung cancer.
ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC
ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.
Laparoscopy Yields Increased Surgical Outcomes in Colorectal Cancer
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
FDA Approves Nogapendekin Alfa-inbakicept/BCG in BCG-unresponsive NMIBC
Nogapendekin alfa-inbakicept is now approved for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer.
Questions Remain Around Neoadjuvant Chemoimmunotherapy in TNBC
Roshni Rao, MD, FACS, discussed the use of neoadjuvant chemoimmunotherapy and its complications in the treatment of patients with triple-negative breast cancer.
7-Gene Predictive Biosignature Helps Predict Ipsilateral Breast Cancer Recurrence
DCISionRT is a risk-assessment test for patients designed to predict RT benefit and develop their recurrence risk after surgery alone or with radiation.
Annamycin Earns European Orphan Drug Designation in Acute Myeloid Leukemia
Preliminary findings from the MB-106 trial support the potential benefit of annamycin/cytarabine in patients with acute myeloid leukemia.
Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery
Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.
Expert Highlights Applications of Proton Therapy in Radiation Oncology
The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.
69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases
Novel Radiotherapy Technology Shows “Great Advantage” in Brain Cancer
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.
70 Navigating Lymphedema: The Impact of Indocyanine Green Lymphography (ICG_L) on Personalized Therapy Outcomes in Patients With Breast Cancer (BC)
Neoadjuvant/Adjuvant Pembrolizumab Regimens Lower RCB in ER+ Breast Cancer
The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.
Clipping of Lymph Nodes May Aid Axillary Surgery in Breast Cancer
In clinically node-positive breast cancer, clipping of lymph nodes may induce higher rates of sentinel lymph node surgery after neoadjuvant chemotherapy.
FDA Mandates New CAR T-Cell Therapy Boxed Warnings in Hematologic Cancers
The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
Omid Hamid, MD, gives his perspective on the use of tumor-infiltrating lymphocyte therapy for patients with melanoma.
Pembrolizumab Prolongs Survival in Clear-Cell RCC
Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.
Nanatinostat Combo Yields Responses in R/R EBV+ Peripheral T-Cell Lymphoma
Phase 2 findings support nana-val as a promising treatment option for those with EBV-positive peripheral T-cell lymphoma.
Striving for Health Care Equity by Closing the Cancer Care Gap
“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”
FDA Approves Pegulicianine-Based Imaging for Breast Cancer Surgery
Results from the INSITE trial support the utility of pegulicianine fluorescence-guided surgery during breast cancer surgery.
COVID-19 Pandemic Has Exacerbated CRC Surgery Disparities
Patients who are African American appeared to have worse clinical stages of colon and rectal cancer during surgery in 2020.
PET Imaging Agent Earns FDA Fast Track Designation in Recurrent Glioma
TLX101 is currently under assessment as a treatment for glioma in the IPAX-2 and IPAX-Linz studies.
Identifying Indications for Neoadjuvant Therapy in Cholangiocarcinoma
The recent Hot Topics section focuses on survival rates for patients with cholangiocarcinoma.
The Role of Molecular Profiling in Optimizing Treatment Decisions for RCC
Molecular profiling is a tool that can best determine first-line therapy options for patients with advanced RCC.
Survival Outcomes Improve With TIL Presence in TNBC
An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.
Increased Thyroid Cancer Risk Not Observed After Use of GLP1 Receptor Agonist
Patients who are predisposed to medullary thyroid cancer should be advised against the use of GLP1 agents.
